Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) announced a peer‑reviewed, randomized double‑blind sham‑controlled trial published in Molecular Psychiatry showing four weeks of its non‑invasive DIFS™ neurostimulation improved attention and normalized brain activity in adults with ADHD.

In 56 adults, active treatment produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale versus 5.5‑points for sham (4.6‑point separation, p < 0.001), plus MEG/EEG evidence of reduced excessive gamma activity and restored network communication. Treatment was well tolerated with no serious adverse events reported.

Positive

• Adult ADHD score improvement: 10.1 points
• Separation vs sham: 4.6 points (p < 0.001)
• Objective MEG/EEG normalization of brain networks
• No serious adverse events; safety comparable to sham

Negative

• Small randomized sample: 56 adults
• Study limited to adults at a single research center

Key Figures

Sample size: 56 adults Treatment duration: 4 weeks Active group improvement: 10.1-point change +5 more

8 metrics

Sample size 56 adults Randomized, double-blind, sham-controlled ADHD trial

Treatment duration 4 weeks Non-invasive DIFS™ neurostimulation period

Active group improvement 10.1-point change Adult ADHD Self-Report Scale at week four

Sham group improvement 5.5-point change Adult ADHD Self-Report Scale at week four

Group separation 4.6-point difference Active vs sham on Adult ADHD Self-Report Scale

P-value p < 0.001 Difference between active and sham ADHD score changes

Gamma activity change Reduction observed Excessive gamma-frequency brain activity by MEG

Serious adverse events None reported Safety profile compared to sham stimulation

Market Reality Check

Price: $0.0138 Vol: Volume 81,457 is below th...

low vol

$0.0138 Last Close

Volume Volume 81,457 is below the 20-day average of 208,783, indicating limited pre-news participation. low

Technical Shares at 0.68 are trading below the 200-day MA of 1.14 and far under the 3.87 52-week high.

Peers on Argus

NXL was down 4.24% while peers were mixed: INBS up 11.8%, NVNO up 0.51%, AIMD do...

1 Down

NXL was down 4.24% while peers were mixed: INBS up 11.8%, NVNO up 0.51%, AIMD down 3.05%, ALUR down 6.01%, CODX down 60.54%. Momentum scanner only flagged XAIR down 22.37% with no news, suggesting stock-specific dynamics rather than a coordinated sector move.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	FDA meeting update	Positive	+1.6%	FDA Q-Submission meeting defined pilot and pivotal Gen-2 SYNC trial plans.
Dec 02	Investor webinar	Positive	+5.4%	Investor webinar highlighting DIFS™, HALO™ headset, and global mental health strategy.
Nov 18	Clinical case report	Positive	-1.9%	Peer-reviewed case report showed promising 15 mA device results in gambling disorder.
Nov 13	Distribution deal	Positive	-7.1%	Exclusive Gen-2 SYNC distribution agreement in Israel after local regulatory approval.
Nov 05	FDA Q-Submission	Positive	-4.3%	FDA accepted Q-Submission for Gen-2 SYNC in Alzheimer’s and dementia.

Pattern Detected

Recent positive regulatory and partnership news often saw mixed to negative next-day price reactions, with more divergences than alignments.

Recent Company History

Over the past months, Nexalin reported several milestones, including FDA Q-Submission acceptance and a substantive meeting for its Gen-2 SYNC™ console targeting Alzheimer’s and dementia (Nov 5 and Dec 3, 2025). It also expanded international distribution to Israel and highlighted promising neuromodulation data in addiction. Investor events and webinars around its DIFS™ technology briefly aligned with positive price moves, but multiple clinically and regulatorily positive updates were followed by negative reactions, underscoring inconsistent market follow-through ahead of this ADHD study publication.

Market Pulse Summary

This announcement details a randomized, sham-controlled ADHD study in 56 adults where Nexalin’s DIFS...

Analysis

This announcement details a randomized, sham-controlled ADHD study in 56 adults where Nexalin’s DIFS™ neurostimulation produced a 4.6-point superiority over sham on the Adult ADHD Self-Report Scale with p < 0.001, alongside EEG and MEG evidence of normalized brain activity. These results add to previously reported neuromodulation findings and ongoing Alzheimer’s regulatory work. Investors may track further controlled trials, broader patient populations, regulatory interactions, and how the company addresses its previously disclosed operating losses and funding plans.

Key Terms

electroencephalography (eeg), magnetoencephalography (meg), randomized, double-blind, sham-controlled trial, gamma-frequency brain activity, +4 more

8 terms

electroencephalography (eeg) medical

"validated with electroencephalography (EEG) and magnetoencephalography (MEG)"

Electroencephalography (EEG) records the brain’s electrical activity through sensors placed on the scalp, capturing patterns of brain waves much like a seismograph records tremors. Investors care because EEG data are used to show how neurological drugs, devices and diagnostic tools affect the brain, influencing clinical trial results, regulatory approvals and market adoption that drive a company’s revenue and development timeline.

magnetoencephalography (meg) medical

"validated with electroencephalography (EEG) and magnetoencephalography (MEG), two non-invasive"

Magnetoencephalography (MEG) is a noninvasive brain-imaging technique that detects the tiny magnetic fields produced by nerve cell activity, like using an extremely sensitive microphone to ‘listen’ to the brain’s electrical conversations. For investors, MEG matters because it can become a tool for diagnosing neurological conditions, guiding treatments, validating drug or device effects, and creating commercial opportunities for companies developing medical imaging equipment, clinical services, or neurotechnology products.

randomized, double-blind, sham-controlled trial medical

"The randomized, double-blind, sham-controlled trial evaluated 56 adults with ADHD"

A randomized, double-blind, sham-controlled trial is a study where participants are randomly assigned to receive either the real medical treatment or a convincing fake version (a 'sham'), and neither the participants nor the researchers know who got which. Like flipping a coin for assignment and keeping the result hidden, this design limits unintentional influence and placebo effects, so results give investors much stronger, clearer evidence about whether a treatment actually works and is safe—information that directly affects regulatory approval, market adoption, and company value.

gamma-frequency brain activity medical

"associated with a reduction in excessive gamma-frequency brain activity—an abnormal pattern"

Gamma-frequency brain activity is a fast, rhythmic pattern of electrical signals in the brain, typically in the 30–100 Hz range, that helps different brain areas sync up when people pay attention, form memories, or process complex information. Investors care because changes in these signals are used as biomarkers and targets for drugs, devices, or diagnostics—like a tuning signal that indicates whether a neurological treatment or product is working and can affect a venture's clinical success and market value.

transcranial alternating current stimulation medical

"Efficacy and safety of transcranial alternating current stimulation in adults with attention"

A noninvasive medical technique that applies very weak, oscillating electrical currents to the scalp through small electrodes to gently influence the brain’s natural rhythms—think of it as using a soft metronome to nudge neural activity. Investors care because it is a growing area for therapeutic devices and clinical research: safety, efficacy, regulatory approval, and patent position can strongly affect commercial potential and the value of companies developing these technologies.

neuroimaging medical

"changes in the participants brain activity measured with advanced neuroimaging."

Neuroimaging is the set of medical techniques that create pictures or maps of the brain’s structure and activity, like using a camera or GPS to see what parts of the brain look like and how they behave. For investors, neuroimaging matters because it provides objective evidence used in clinical trials, product development and regulatory decisions, helping judge whether a therapy or device is likely to work, reduce risk, and reach the market.

neurostimulation medical

"Nexalin’s DIFS™ neurostimulation technology produced positive and objective changes"

Neurostimulation is a medical technique that uses controlled electrical or magnetic pulses to change activity in nerves or the brain, similar to how a pacemaker helps regulate a heartbeat. It matters to investors because devices and therapies using this approach can create new revenue streams or risks depending on clinical results, regulatory approvals, insurance coverage and how widely doctors and patients accept the treatment.

neuromodulation medical

"represents a fundamentally different, drug-free approach to neuromodulation."

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

AI-generated analysis. Not financial advice.

Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changes

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating  Nexalin’s Deep Intracranial Frequency Stimulation (DIFS™) technology produced positive and objective changes in the participants brain activity measured with advanced neuroimaging. The adult patient population treated in the study suffered from a neurodevelopment disorder known as Attention Deficit Hyperactive Disorder (ADHD). Nexalin’s frequency-based waveform influences cognitive performance by altering the electrical activity of the neurons in the brain to enhance and improve how the networks in the brain function. This improvement in brain function was validated with electroencephalography (EEG) and magnetoencephalography (MEG), two non-invasive brain imaging techniques used to measure electrical and magnetic activity in the brain. Participants receiving active treatment also experienced a dramatic reduction in ADHD symptoms.

The randomized, double-blind, sham-controlled trial evaluated 56 adults with ADHD who received four weeks of Nexalin’s non-invasive frequency-based neurostimulation. In addition to improvements in the EEG and MEG, participants receiving active treatment demonstrated significantly greater improvement in inattentive symptoms compared to those receiving sham stimulation, with benefits emerging within the first two weeks and peaking at the end of the four-week treatment period. At week four, patients receiving active stimulation showed a 10.1-point average improvement on the Adult ADHD Self-Report Scale– compared to a 5.5-point average improvement in the sham group, representing a 4.6-point separation between groups (p < 0.001). The data from the active and sham groups represents a clear and statistically significant improvement over sham stimulation.

Importantly, the study extended beyond traditional symptom-based assessments. Researchers incorporated magnetoencephalography (MEG), a highly sensitive, non-invasive brain imaging technique that measures real-time neural activity, allowing investigators to directly evaluate changes in brain network function associated with attention and cognitive control.

MEG analysis showed that Nexalin’s DIFS™ technology was associated with a reduction in excessive gamma-frequency brain activity—an abnormal pattern commonly observed in individuals with ADHD and other mental health issues linked to racing thoughts, distractibility, and difficulty sustaining attention and difficulty in social engagements. Additionally, these symptoms are frequently associated with anxiety, depression and insomnia.

Following treatment, researchers observed normalization of communication between key brain networks involved in attention and focus. These same networks are also linked to memory, emotion, cognitive control and social awareness. In practical terms, the imaging findings suggest that Nexalin’s deep, frequency-specific neurostimulation helped reduce the brain’s overactive neuronal signaling and improve coordination across brain regions critical to healthy brain function.

These objective brain imaging findings were consistent with clinical outcomes. Adults receiving active Nexalin-based stimulation experienced significant improvement in their ability to concentrate, as well as reductions in ADHD symptoms and improvements in mood and sleep quality. The treatment was well tolerated, with a safety profile comparable to sham stimulation and no serious adverse events reported.

“This study represents an important milestone for Nexalin and for the field of non-invasive neurostimulation,” said Mark White, CEO of Nexalin Technology. “I have stated several times that Nexalin Technology represents a major breakthrough in non-invasive stimulation of the brain. Nexalin is a whole brain neurostimulation medical device, not another battery operated internet device sold to consumers. What makes these results particularly compelling is that the clinical improvements were supported by objective brain imaging data. Seeing measurable normalization of abnormal brain activity—especially in networks tied to mood, sleep, attention and focus. These clinical improvements reinforce our belief that Nexalin’s DIFS™ technology can address underlying neural dysfunction associated with complex mental health conditions.”

Dr. David Owens, Chief Medical Officer of Nexalin, added, “From a clinical and scientific standpoint, this study is significant because it moves beyond symptom checklists and directly examines how the brain is functioning. The use of MEG allowed researchers to observe reductions in excessive gamma activity and improvements in functional brain networks. These findings provide valuable insight into how deep, frequency-specific neurostimulation may help regulate abnormal neural signaling that contributes to attention deficits, while maintaining a strong safety profile.”

The study, titled, “Efficacy and safety of transcranial alternating current stimulation in adults with attention deficit hyperactivity disorder: a double-blind randomized sham-controlled trial,” was conducted by researchers at Peking University Sixth Hospital and published online in Molecular Psychiatry in December 2025. The trial utilized Nexalin-manufactured neurostimulation equipment and incorporated MEG imaging to evaluate both clinical outcomes and underlying brain network changes.

While the study was conducted in adults, the findings reflect a broader scientific shift toward understanding mental health conditions as disorders of brain network regulation rather than isolated chemical imbalances. ADHD affects millions of individuals worldwide, and current treatment approaches often rely on pharmaceutical therapies that may not directly address underlying neural dysregulation and can be associated with unintended side effects. By directly measuring and influencing abnormal brain activity—rather than relying on symptom relief alone—Nexalin’s DIFS™ technology represents a fundamentally different, drug-free approach to neuromodulation.

Nexalin designs and develops innovative neurostimulation products to help address the global mental health epidemic. Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology is non-invasive, drug-free, and designed to modulate disrupted brain networks associated with mental health disorders. Nexalin’s neurostimulation devices are approved in multiple international markets, and the Company continues to advance research across a range of neurological and psychiatric conditions.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

FAQ

What were the main clinical results for Nexalin (NXL) in the January 14, 2026 study?

Active DIFS™ produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale vs 5.5 for sham, a 4.6‑point separation (p < 0.001).

Did the Nexalin (NXL) study include objective brain imaging evidence?

Yes; investigators used MEG and EEG and reported reduced excessive gamma activity and improved network communication after active DIFS™.

How long was the Nexalin (NXL) treatment in the ADHD trial and when did benefits appear?

Treatment lasted four weeks; benefits emerged within two weeks and peaked at week four.

Was the Nexalin (NXL) neurostimulation treatment safe in the trial?

Yes; the trial reported the treatment was well tolerated with no serious adverse events and a safety profile comparable to sham.

Where and when was the Nexalin (NXL) study published?

The randomized double‑blind sham‑controlled trial was published online in Molecular Psychiatry in December 2025.